Recombinant factor VIII liposomal (Opperbas/Omri)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant factor VIII liposomal (Opperbas/Omri)

Drug Alias NameRecombinant F VIII liposomal (Opperbas/Omri)重组凝血因子VIII脂质体（Opperbas/Omri）Factor VIII liposomal (Opperbas/Omri)F VIII liposomal (Opperbas/Omri)

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor

Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation

TargetsCoagulation factor X

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesOmri Laboratories Opperbas Holding

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOpperbas Holding Omri Laboratories

Active IndicationsN/A

Inactive IndicationsHemophilia A

Other Information

ATC CodeN/A